C54 (Amlodipine Besylate, Hydrochlorothiazide and Olmesartan Medoxomil 5 mg / 25 mg / 40 mg)
Pill with imprint C54 is Yellow, Elliptical / Oval and has been identified as Amlodipine besylate, hydrochlorothiazide and olmesartan medoxomil 5 mg / 25 mg / 40 mg. It is supplied by Sun Pharmaceutical Industries Inc..
Amlodipine/hydrochlorothiazide/olmesartan is used in the treatment of high blood pressure and belongs to the drug class miscellaneous antihypertensive combinations. There is positive evidence of human fetal risk during pregnancy. Amlodipine/hydrochlorothiazide/olmesartan 5 mg / 25 mg / 40 mg is not a controlled substance under the Controlled Substances Act (CSA).
Images for C54
- 5 mg / 25 mg / 40 mg
- Elliptical / Oval
- Prescription only
- Drug Class:
- Miscellaneous antihypertensive combinations
- Pregnancy Category:
- D - Positive evidence of risk
- CSA Schedule:
- Not a controlled drug
- Labeler / Supplier:
- Sun Pharmaceutical Industries Inc.
- National Drug Code (NDC):
More about amlodipine/hydrochlorothiazide/olmesartan
- Amlodipine/hydrochlorothiazide/olmesartan Side Effects
- During Pregnancy
- Dosage Information
- Drug Images
- Drug Interactions
- Support Group
- Pricing & Coupons
- En Español
- 18 Reviews – Add your own review/rating
- Drug class: miscellaneous antihypertensive combinations
- Amlodipine, hydrochlorothiazide, and olmesartan
- Olmesartan, Amlodipine, and Hydrochlorothiazide
- Olmesartan, amlodipine, and hydrochlorothiazide (Advanced Reading)
Other brands: Tribenzor
- Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide (FDA)
- Olmesartan, Amlodipine, and Hydrochlorothiazide (Wolters Kluwer)
Related treatment guides
Every effort has been made to ensure that the information provided is accurate, up-to-date, and complete, but no guarantee is made to that effect. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Copyright 2018 Drugs.com, National Library of Medicine, Truven Health Analytics and Cerner Multum, Inc. All Rights Reserved.